Vicente-Ayuso, García-Roa, González-Fernández, Álvarez-Carmona, Benavente-Cuesta, Mateo-Morales, Pérez-López, Peña-Cortijo, Zarzuela, Gutiérrez, and Martínez-Martínez: Therapy-related myeloid neoplasms as a concerning complication in acute promyelocytic leukemia

Therapy-related myeloid neoplasms as a concerning complication in acute promyelocytic leukemia




Competing interest statement

Conflict of interest: the authors declare no potential conflict of interest.

Abstract

Acute promyelocytic leukemia (APL) has become a highly curable malignant disease after the introduction of all transretinoic acid (ATRA) to chemotherapy treatment. However, the risk to develop therapy-related myeloid neoplasms (t-MN) has become a matter of concern, as APL patients are otherwise expected to have a good prognosis. We report a patient with APL who achieved complete remission after chemotherapy induction with anthracycline and ATRA, followed by consolidation and maintenance chemotherapy. Two years later, the patient developed t-AML, with MLL rearrangements, without any evidence of relapse of the APL original clone. The increasing incidence of t-MN in oncohematological patients is partly due to the development of safer, more efficient or targeted therapies, which allow better outcomes and lengthened survival amongst treated patients. The identification of genetic factors, mechanisms or prognostic biomarkers in t-MN might open new windows for the development of personalized targeted therapy regimes in this underserved patient population.

Introduction

Acute promyelocytic leukemia (APL), also known as acute myeloid leukemia (AML) M3 subtype of the French- American-British (FAB) classification, is a highly fatal subtype of AML. It is caused by t(15;17), a translocation that results in the fusion of the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor alpha (RARA) gene on chromosome 17, which also serves as a clone specific molecular marker for diagnosis and monitoring.1

This unique molecular abnormality allows targeted therapy, making APL highly curable. In the past, anthracycline and cytosine arabinoside (Ara-C) based combination chemotherapy yielded cure rates of only 35-40% in APL patients, whereas the introduction in the early 1990s of all trans-retinoic acid (ATRA) to the chemotherapy regime, in combination with anthracycline-Ara C or anthracycline alone, has improved the cure rate to 80-90%. However, recent reports suggest an increasing risk in APL patients to develop therapy-related myeloid neoplasms (t-MN).2-7 t-MN are clonal hematopoietic disorders that arise due to iatrogenic somatic mutations that increase proliferative capacity and survival advantage of the affected hematopoietic progenitors. They are considered as a subgroup of its own in the revised 2016 WHO classification, comprising myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) patients who were exposed to cytotoxic or radiation therapy for an unrelated malignancy or an autoimmune disease (i.e. multiple sclerosis or rheumatologic disease).8 Both, t-MDS and t-AML are combined in one entity due to their similar pathogenesis, rapid progression from t-MDS to t-AML, and their equally poor prognosis with no differences in outcome. Moreover, t-MN should be distinguished from AML with myelodysplasia (secondary AML), which is diagnosed either when 50% or more of the bone marrow cells are dysplastic in at least two lineages, when the patient had a previous diagnosis of MDS or MDS/MN or when myelodysplasia-associated cytogenetic aberrations are present.3,4

Hereby, we report a patient with APL who presented complete clinical and molecular remission after chemotherapy. Two years after diagnosis, the patient developed t-AML with MLL rearrangements, without any evidence of relapse of the APL original clone. This clinical manifestation, i.e. t- MN, though rare, has been increasingly diagnosed and is a matter of concern in treated APL patients, who are otherwise expected to have a good prognosis after targeted therapy.

Case Report

A 46-year-old woman presented with spontaneous bruises and pancytopenia in 2008. Complete Blood Counts (CBC) measured showed a hemoglobin concentration of 10.7 g/dL, a leukocyte count of 1.2×106/mL (with differential of 30% neutrophils, 40% lymphocytes and 30% blasts), and a platelet count of 18×106/mL (Figure 1). Screen coagulation was normal. Peripheral blood smear and bone marrow aspiration were suggestive of an infiltration of 90% of abnormal promyelocytes and blasts (Figure 2A). Bone marrow flow cytometry analysis confirmed the aberrant population (77.5% of viable cells) immunophenotyped as CD33+|CD45+ |CD117mid with a CD13+ homogeneous scattered pattern and MPO+, and negative for HLA-DR, CD34, CD123, CD14, CD15, CD64, CD42A, and GPA (Figure 2B and data not shown). Cytogenetic analyses revealed t(15; 17) and PML/RARA rearrangement, without identifying other secondary genetic lesions. She completed chemotherapy treatment according to the Spanish Program of Treatments in Hematology (PETHEMA) 2005 protocol for patients with intermediate risk APL (induction with ATRA and Idarubicin, three cycles of consolidation and maintenance with Mercaptopurine, methotrexate and ATRA), after which complete hematological and molecular remission (CR) was observed (Figure 1).

In September 2010, the patient presented with leucopenia and thrombocytopenia (Figure 1). Cytology and flow cytometry of bone marrow aspirate showed 7% of blasts with dysplasia AREB-II versus AML that were immunophenotyped as CD117+|CD45+|CD33++ and negative for CD34 and HLA-DR, suggestive of an early stage of relapse (Figure 3A). The main differential diagnosis was established between a relapse of APL or a different subtype of AML secondary to treatment (t-AML). APL was discarded since t(15; 17) was not detected. A t-AML relapse was confirmed on peripheral blood smear cytology two weeks later (Figure 3B) and bone marrow aspirate containing 70% of blasts. From the karyotype, a 46XX cell clone containing rearrangements on the MLL gene was identified, with breakpoints in chromosomes 20q12 and 11q23, corresponding to unfavorable European Leukemia NET (ELN) Score. With a diagnosis of t-AML in a patient with previous history of treated APL, she received two cycles of chemotherapy with Idarubicin and Ara-C (7+3 induction regimen), reaching CR with negative minimal residual disease (MRD), and without MLL gene rearrangements, which she maintained after consolidation with Ara-C at high doses. In March 2011, allogenic hematopoietic cell transplantation (HCT) was performed (Figure 1).

After four years suffering serious symptoms related to chronic skin (grade II) and hepatic (grade III) GvHD, she presented with pancytopenia and a suspicion of relapse of t-AML in April 2015, later confirmed on bone marrow cytologic and immunophenotypic studies. She deceased due to a septic shock of respiratory origin before further treatment could be initiated.

Discussion

The recent increase in the number of reports of t-MN (t-AML) in treated APL patients, allows epidemiologic analysis of its occurrence. Relapse after CR with a different subtype of AML is rare (between 1% and 6.5% of reported cases),6 while relapse as APL occurs in 10-15% of the cases.9 t- MN is predominant in women, which can be partly explained by the fact that the most frequent primary malignancy is breast cancer followed by non-Hodgkin lymphoma. The risk to develop t-MN has increased during the last three decades in non-Hodgkin lymphoma, while it has declined in ovarian cancer and multiple myeloma, and it has remained constant in breast cancer and Hodgkin lymphoma. t-MN appears at any age, but the median age at diagnosis is 61 years.2-7 It is necessary to consider several covariates responsible for the increased risk of t-MN, including age, time since prior therapy (i.e. latency period), type of chemotherapy and cumulative dose, use of combined modality regimes (chemotherapy and radiation), and dose and volume of radiation applied. In this context, the origin of a t-MN clone, different from the original, could be due to a number of collateral causes. i) The t-MN clone co-exists with the original APL clone at diagnosis, however, not being affected by APL targeted therapy, it overgrows after CR. The incidence of cooccurrence of additional cytogenetic abnormalities (ACA) at initial diagnosis in APL patients has been reported in one-third of analyzed cases. However, there is no evidence that the presence of ACA at the time of diagnosis correlates with the outcome in APL patients.10

The high frequency of TP53 mutations found in patients with t-MN (approximately one third of them) supports the notion of cooccurring treatment-resistant clones. It has been reported that malignant clones bearing TP53 mutations require two induction courses to achieve CR, suggesting relative chemotherapy resistance.11 Other genes with a mutation frequency of > 5% in t-MN include NPM1, FLT3-ITD, TET2, DNMT3A, STAG2, ABC transporter genes, IDH1, IDH2, RUNX1 and ASXL1 amongst others.2-7,11-14

ii) The t-MN clone is induced by therapy, as it is known that the drugs used and the patient genetic susceptibility may play a role. The pathogenesis can be explained by direct induction of an oncogene through chromosomal translocations or genetic instability. Several types of cytotoxic agents, such as topoisomerase II (TOP2) inhibitors, alkylating agents, antimetabolites, and antitubulin agents, in addition to radiotherapy, have been associated with t- MN. t-MN that develops after treatment with TOP2 inhibitors, such as etoposide or anthracyclines, are associated to fusion oncogenes such as KTM2A/MLL-MLLT3, have a latency of 2 to 3 years and a better prognosis. In contrast, treatment with alkylating agents has been associated with adverse cytogenetics (i.e. unbalanced aberrations of chromosomes 5 and 7 and/or complex karyotype), a longer latency and a poor prognosis.3-5,7,12-14 To date, there is no pathognomonic genetic or morphologic profiling of t-MN. Inherited cancer susceptibility may explain why patients develop more than one type of malignancy, especially under cytotoxic therapy, due to DNA damage in genes such as BRCA1, BRCA2, BARD1, TP53, RAD51 and HLX1, Fanconi genes, and the anti-apoptotic gene BCL2L10.2-5,7,12-14

iii) The t-MN clone is induced due to a lineage shift within the myeloid compartment as a virtue of hematopoietic stem cell plasticity. The hematopoietic system homeostasis, affected by the initial disease and/or therapy, responds by inducing potential epigenetic changes favoring abnormal lineage maturation, resulting in non-restrictive proliferation of a non-APL aberrant clone. It has been reported that changes in the microenvironment composition might lead to disease, although how any of these alterations would promote lineage switching in leukemia is largely unknown.15

We report a patient diagnosed with APL (AML M3) who developed t-AML after achieving complete hematological and molecular remission upon targeted therapy. A relapse of the original APL clone was discarded and MLL rearrangements were identified, confirming a different subtype of AML responsible of the patient’s t-AML.

The patient was treated with Idarubicin, a topoisomerase II (TOP2) inhibitor, that has been related with t-AML, and MLL rearrangements. The fact that MLL rearrangements were not identified in our patient with the original APL clone at time of diagnosis, together with the timing and cytogenetic aberration of the relapse clone, suggest the patient suffered from t-AML due to TOP2 treatment. At the time our patient was studied, TP53 mutations and other genetic susceptibility associations were not well established, and thus, they were not investigated. A lineage switch hypothesis seems less likely, since genetic aberrations in APL and secondary leukemia are driven by different genetic drivers.

Prognosis of t-MN is poor with a median survival of less than a year.5,7 It has been suggested that malignant cells with multiple aberrations are more immunogenic than cells with one or a few aberrations, and thus novel immune-based therapies, such as chimeric antigen-receptor T cells, bi-specific antibodies, and checkpoint inhibitors, should be considered in t-MN with a highrisk genetic profile and their evaluation in clinical trials should be encouraged.4 Cytogenetic classification of t-AML should be further evaluated as a potential prognostic marker, and treatment recommendations should be based on performance status and karyotype. Recent unbiased approaches driven by gene expression analysis and Next Generation Sequencing have contributed to the identification of unique biomarkers associated with leukemia, which have the potential to significantly improve the diagnostic and prognostic criteria, and contribute to the continuous adaptation of treatment protocols.13

Conclusions

We can conclude the following: i) t- MN, though rare, is increasing its occurrence as the survival in onco-hematological patients lengthens. It is therefore a matter of concern in treated APL patients, who are otherwise expected to have good prognosis. ii) t-MN prognosis is uniformly dismal. iii) A better understanding of potential genetic factors or mechanisms around the occurrence of t-MN might open new windows for the development of personalized therapy regimes in this underserved patient population.

References

1. 

MS Tallman, JK Altman. How I treat acute promyelocytic leukemia. Blood 2009;114:5126-35.

2. 

CE Bueso-Ramos, R Kanagal-Shamanna, MJ Routbort, CA Hanson. Therapyrelated myeloid neoplasms. Am J Clin Pathol 2015;144:207-18.

3. 

A Ganser, M. Heuser Therapy-related myeloid neoplasms. Curr Opin Hematol 2017;24:152-8.

4. 

M Heuser. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematol Am Soc Hematol Educ Program 2016:24-32.

5. 

VM Klimek, NJ Tray. Therapy-related myeloid neoplasms: what’s in a name? Curr Opin Hematol 2016;23:161-6.

6. 

R Latagliata, MC Petti, S Fenu. Therapy-related myelodysplastic syndrome- acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002;99:822-4.

7. 

K Sasaki, E Jabbour, J Cortes. Outcome of patients with therapy-related acute myeloid leukemia with or without a history of myelodysplasia. Clin Lymphoma Myeloma Leuk 2016;16:616-24.

8. 

DA Arber, A Orazi, R Hasserjian. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405.

9. 

MRF Hessenauer, N. Gangat Incidence and management of relapsed acute promyelocytic leukemia. In: Blood, editor. 58th ASH Annual Meeting 2016. p. 5179.

10. 

S De Botton, S Chevret, M Sanz. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000;111:801-6.

11. 

TN Wong, G Ramsingh, AL Young. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015;518: 552-5.

12. 

ESS AE, S Chacim, I Ferreira. Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia. Oncol Lett 2016;12:262-8.

13. 

MF Zahid, A Parnes, BN Savani. Therapy-related myeloid neoplasms - what have we learned so far? World J Stem Cells 2016;8:231-42.

14. 

L Zhang, SA Wang. A focused review of hematopoietic neoplasms occurring in the therapy-related setting. Int J Clin Exp Pathol 2014;7:3512-23.

15. 

J Purizaca, I Meza, R. Pelayo Early lymphoid development and microenvironmental cues in B-cell acute lymphoblastic leukemia. Arch Med Res 2012;43:89-101.

Figure 1.

Schematic representation of the evolution of the reported case. The X-axis depicts time (year). The upper part of the scheme shows hemoglobin levels (Hb, red dots and corresponding Y-axis within red-shaded block), platelet counts (PLTs, brown dots and corresponding Y-axis within brown-shaded block) and neutrophil counts (NEUT, blue dots and corresponding Y-axis within blue-shaded block) as measured at the indicated times (vertical dashed lines). In the lower part of the scheme, the clinical status and treatment given at the indicated times (vertical dashed lines) is highlighted. APL: acute promyelocytic leukemia; t-AML: therapy related acute myeloid leukemia; CR: complete remission; HCT: allogenic hematopoietic cell transplantation.

hr-9-3-7204-g001.jpg
Figure 2.

A) Representative pictures of peripheral blood (PB) smear at time of APL (AML M3) diagnosis (Hematoxylin & Eosin staining, magnification ×100). B) Flow cytometry analysis of bone marrow aspirate at time of APL diagnosis. Dot plots are depicted: the gated population is indicated on top of each dot plot. The CD45mid population was plotted against CD15 and CD33, and CD33+CD15- aberrant blasts (orange population in the dot plots) were further analyzed for expression of a series of markers, i.e. surface CD117, CD34, HLA-DR, CD13 and intracellular (IC) MPO.

hr-9-3-7204-g002.jpg
Figure 3.

A) Flow cytometry analysis of bone marrow aspirate at time of t-AML diagnosis. Dot plots are depicted: the gated population is indicated on top of each dot plot. The CD45mid population was plotted against CD15 and CD33, and CD33+CD15mid aberrant blasts (orange population in the dot plots) were further analyzed for expression of a series of markers, i.e. surface CD117, CD34 and HLA-DR. B) t-AML as observed in peripheral blood (PB) smear, showing increased intermediate-size blasts with a basophilic granular cytoplasm, some of them presenting Auer rods (arrowheads), (Hematoxylin & Eosin staining, magnification ×100). APL: acute promyelocytic leukemia; t-AML: therapy related acute myeloid leukemia.

hr-9-3-7204-g003.jpg
Abstract views:
320

Views:
PDF
74
HTML
102

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 María del Carmen Vicente-Ayuso, María García-Roa, Ataúlfo González-Fernández, Ana María Alvarez-Carmona, Celina Benavente-Cuesta, Marta Mateo-Morales, Cristina Pérez-López, Ascensión Peña-Cortijo, Marta Polo Zarzuela, Laura Gutiérrez, Rafael Martínez-Martínez

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy